ArticleJournal of inflammation research2026
Screening and Preliminary Validation of Parthanatos-Related Key Genes in Asthma Using Transcriptomic and Machine Learning Approaches.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Parthanatos, a Poly polymerase 1 mediated programmed cell death pathway, remains poorly characterized in asthma pathogenesis. This study integrated transcriptomic data from public asthma datasets and parthanatos-related genes (PRGs) to identify the key molecular players. Patients and Methods: Asthma-related datasets GSE69683 (411 asthma and 87 control samples) and GSE134544 (10 asthma and 21 control samples) were obtained from public databases. Through differential expression analysis, weighted gene co-expression network analysis (WGCNA), and machine learning, three genes (ANXA3, CEACAM6, and 8d) were prioritized. Functional enrichment linked these genes to inflammatory and metabolic pathways, including complement/coagulation cascades, spliceosomes, and citrate cycle. Results: Immune infiltration analysis revealed significant disparities in naive B cells, eosinophils, neutrophils, resting mast cells, and CD8 + T cells between asthmatic and control groups. These genes are correlated with lung injury, neoplasms, and broader respiratory diseases, highlighting their clinical relevance. Predictive analysis identified environmental compounds (eg benzo(a)pyrene, and estradiol) interacting with all three genes, suggesting therapeutic targets. Preliminary experimental validation via RT-qPCR suggested the upregulation of CEACAM6 and CRISP3 expression in asthmatic blood samples. Conclusion: In conclusion, we identified and preliminarily validated ANXA3, CEACAM6, and CRISP3 as parthanatos-related key genes in asthma, providing a foundational gene signature for subsequent research into asthma diagnostics and mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.